Introduction
Since the rise of tissue engineering, the development of biological substitutes in medical research has been a key issue in order to develop new strategies to replace lost or damaged tissues. The research field focused on new tissue formation is improving day by day, and it is nowadays facing the problem of poor tissue vascularization. [1] [2] [3] [4] The angiogenic process, which takes place within the scaffolds, is adequate to allow cellular oxygen supply, whereas it might not be sufficient to sustain tissue survival. Thus, in order to improve tissue vascularization, several approaches are currently under investigations, such as the addition of angiogenic factors, the seeding of cells engineered for the production of growth factors within the scaffold or the development of microsurgical strategies.
Focusing on the usage of factors, several attempts have already been developed by the use of one or more recombinant proteins either alone or in combination such as vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF) or platelet-derived growth factor b (PDGF-b) leading to promising results that were shown to be affected by the short half-life of the recombinant factors. 5 Therefore, studies aimed to control the protein release from the scaffold, for instance by the application of slow release devices or modified matrix, were developed and led to better results suggesting that these approaches might be feasible. [6] [7] [8] [9] [10] Moreover, concerning the microsurgical techniques, a promising approach has been developed by Morrison, who has combined tissue engineering and microsurgery. [11] [12] [13] Focusing on the development of innovative approaches to enhance the formation of new blood vessel and, most importantly, the generation of a vascularized new tissue within a scaffold, a novel promising method has been described, based on a microsurgical arterio-venous loop (AVL) embedded in a collagen-based matrix. 14 In this model, the main driver for blood vessel formation has been identified in the shear stress within the vessels of the AVL. 4 A research area that is nowadays opening a new scenario in the tissue engineering field is gene therapy, which might be combined with the previously described approaches to improve them and to overcome their limitations. The use of recombinant vectors for the production of secreted proteins is widely used in research, [15] [16] [17] and clinical trials have already been performed, such as for the treatment of haemophilia. 18, 19 Among the different viral vectors that have been used so far, recombinant adeno-associated viral (rAAV) ones are emerging as feasible candidates for gene therapy due to their appealing features. Of interest, they are able to transduce post-mitotic cells and are characterized by a high tropism for skeletal muscle. Moreover, rAAVs can persist in the transduced cells, leading to long-lasting protein expression. We herein suggest a modification of the novel microsurgically induced regeneration chamber with the insertion of a muscle flap, which can be transduced by rAAVs leading to the secretion of VEGF that eventually will induce an enhancement of the already documented creation of newly formed fibrovascular tissue inside the chamber.
Hence, we propose an approach that combines adenoassociated viral (AAV)-based gene therapy, a collagen scaffold, the pectineus muscular flap and a microsurgical AVL. The pectineus muscular flap is, in the proposed model, inserted into the tissue chamber, presenting also the AVL, and injected with AAV vector encoding human VEGF 165 (AAV-VEGF 165 ) in order to induce the production of VEGF inside the chamber that might improve the angiogenic process and might eventually foster the growth of the implant.
Material and methods

Animals
In all, 21 adult male Wistar rats, weighting 300-350 g, were used for this study. All procedures were carried out under general anaesthesia using Zoletil (Virbac, Carros, France) 40 mg/kg in combination with xylazine (Sigma Aldrich, St. Louis, MO, USA) 15 mg/kg intramuscularly (i.m.). During surgery and for the following 10 days, rats were treated with heparin in order to avoid the formation of thrombi within the AVL forming vessels. The animals were housed in single cages and fed ad libitum.
Animal care and treatment were conducted in conformity with institutional guidelines in compliance with national and international laws and policies (EEC Council Directive 86/609, OJL 358, 12 December 1987) after institutional review board approval.
Generation of the collagen chamber
A previously described AVL model was modified: 14 a vein graft was harvested from one groin and used as a microvascular loop between the femoral artery and vein in the contralateral leg. End-to-side anastomoses were performed with 11/0 nylon sutures on both recipient artery and vein. Then, the vein graft was harvested as long as possible (about 2.4 cm) to enhance angiogenesis from the loop; the previously described chamber was closed folding the template on itself and suturing its free margins together. As the template is enveloped by a silicone layer, the outer envelope of the chamber is silicone; this model of the chamber encloses the AVL and has been demonstrated as a valid system for fostering neovascularization as well as new loose connective tissue formation. In order to test whether we were able to improve the formation of new tissue within the collagen chamber, we added an element to this model, represented by a muscle flap. Skeletal muscle has already been shown to be efficiently transduced by rAAVs. In order to preserve muscle integrity, we conceived a model of local muscle flap (pedicled), and due to the anatomical location, we chose the pectineus muscle as the target tissue to be inserted into the chamber for rAAV transduction. The pectineus flap, comprising its proximal part and sizing mostly 1 cm, was elevated and left pedicled under microscope magnification. One or two delicate stitches were tied to fix the muscle to the collagen matrix and to avoid residual contraction. The dermal template (INTEGRA™) was then folded on itself, maintaining the outer silicon layer, and secured by some suture stitches as a sandwich including the loop and the muscular flap (Figure 1(A) ).
Adult male Wistar rats were divided into three groups (n = 7 per group) according to the treatment (no muscle, AAV vector expressing the reporter gene β-galactosidase (AAV-LacZ) and AAV-VEGF 165 ); the tissue chamber was created as previously described and the isolated muscular flap was injected with 50 µL of either a control AAV-LacZ or the human VEGF 165 isoform (AAV-VEGF 165 ) ( Figure  1(A) ), and the chamber was then closed. The first group acted as control. After 30 days, dermal implants were excised and analysed to detect the formation of new tissue and the presence of vessels. A schematic representation of the experimental flow chart is reported in Figure 1(B) .
Recombinant AAV vectors
The rAAV vectors used in this study were produced by the AAV Vector Unit (AVU) at ICGEB Trieste (http://www. icgeb.org/avu-core-facility.html), according to the established procedures. [20] [21] [22] AAV2 vectors are used in this study, due to serotype tropism for skeletal muscles, and they express either VEGF 165 or β-galactosidase complementary DNA (cDNA) under the control of the constitutive cytomegalovirus (CMV) immediate early promoter. All the viral stocks used had a titre ⩾ 1 × 10 12 viral genome particles/mL. A schematic representation of rAAVs is reported in Figure 1 (C).
Histochemistry, immunofluorescence and morphometric analysis
On day 30, tissue chambers were harvested, following the previously described techniques. 14 Briefly, rats were anaesthetized, the chambers were exposed, vessels were ligated proximally and distally and the specimens were harvested and immediately fixed in 10% formalin and embedded in paraffin. The 5-µm histological sections were stained with Azan trichrome staining (BioOptica, Milan, Italy) or processed for immunofluorescence. The following primary antibodies were used: Cy3-coniugated anti-alpha smooth muscle actin (α-SMA) primary antibody (clone 1A4; Sigma) diluted 1:200 in blocking buffer was used to label smooth muscle cells/pericytes and myofibroblats. Anti-vimentin (sc-6260; Santa Cruz Biotechnology, Dallas, USA) diluted 1:50 in blocking buffer was used to label fibroblasts, and heatinduced antigen retrieval at pH 6 was performed; AlexaFluor 594 anti-mouse antibody (Molecular Probes, Thermo Fisher Scientific, Whaltman, MA USA) diluted 1:500 in blocking buffer was used as secondary antibody. Fluorescein-labelled Lycopersicon esculentum Lectin (FL-1171; Vector Laboratories, Burlingame, CA, USA) diluted 1:100 in blocking buffer was used to label endothelial cells. 4′,6-diamidino-2-phenylindole (DAPI) (Vectashield, Vector Laboratories, Burlingame, CA, USA) fluorescent staining was used to recognize cell nuclei. Images were acquired at room temperature with a DMLB upright fluorescence microscope (Leica Microsystems, Wetzlar, Germany) equipped with a chargecoupled device camera (CoolSNAP CF; Roper Scientific, Trenton, NJ, USA) using MetaView 4.6 quantitative analysis software (MDS Analytical Technologies, Toronto, Canada). Images from Azan trichrome-stained sections were acquired by Leica Laser Microdissector LMD7000 (Leica Microsystems) equipped with a three charge-coupled device colour Hitachi HV-C20A camera (Hitachi, Tokyo, Japan) using Leica IM 1000 software (Leica Microsystems). For the quantification of the tissue within the chamber, the whole area occupied by the stained tissue was quantified by the use of ImageJ software. For the quantification of vessel number, at least 10 fields for each section were analysed. Relative areas occupied by differently stained cells were quantified by the use of ImageJ software.
DNA extraction and AAV detection within the tissue chamber
DNA was extracted from paraffin-embedded specimens, and five sections (50 µm) were deparaffinized, hydrated and digested with proteinase K. DNA content was quantified by means of the Qubit fluorometer (Invitrogen); 50 ng was subsequently used for AAV quantification performed by real-time polymerase chain reaction (PCR), using predeveloped and custom-designed assays (Applied Biosystems, Thermo Fisher Scientific, Whaltman, MA, USA). Values are expressed as the number of viral genome copies (vgc) per microgram genomic DNA using an external calibration curve. A list of the assays used is reported in Table 1 . Amplifications were carried out in a CFX96 RealTime PCR Detection System (Bio-Rad Laboratories, Hercules, CA USA).
RNA isolation and transgene expression analysis
RNA was extracted from frozen samples using TriZol reagent (Life Technologies, Thermo Fisher Scientific, Whaltman, MA, USA) and reversed transcribed using hexamerix random primers (Life Technologies, Thermo Fisher Scientific, Whaltman, MA, USA). The cDNA was subsequently used for transgene expression analysis performed by real-time PCR; the housekeeping gene hypoxanthine guanine phosphoribosyltransferase (HPRT) was used to normalize the results. A list of the assays used is reported in Table 1 . Amplifications were carried out in a CFX96 Real-Time PCR Detection System (Bio-Rad).
Statistics
Data are presented as mean ± standard error of the mean (SEM). Pair-wise comparison between groups was performed using the Student's t-test, whereas one-way analysis of variance (ANOVA) and Bonferroni post hoc tests were used to compare multiple groups. A value of p < 0.05 was considered statistically significant.
Results
Description of the model and detection of AAV within the tissue chamber
We herein propose a modification of a previously described AVL model by means of a gene therapy approach. In order to create an AVL, a vein graft was harvested from one groin and used as a microvascular loop between the femoral artery and vein in the contralateral leg. End-to-side anastomoses were performed with 11/0 nylon sutures on both recipient artery and vein. The AVL was created on a collagen-based template, and a muscular flap from the pectineus muscle was inserted in close proximity and transduced by rAAVs. The muscle was chosen as a target tissue due to the high tropism of rAAV, serotype 2, for the skeletal muscle. The described chamber was then closed folding the template on itself and suturing its free margins together. In order to confirm the presence of the injected vectors within the chamber, we analysed DNA extracted from the samples isolated 30 days after surgery and quantified the viral load by means of real-time PCR, as described in section 'Material and methods'. In all the samples, we were able to detect the presence of rAAV genomes, as reported in Figure 1(D) . Moreover, we analysed the expression of the transgene, and we could detect the expression of human VEGF in the AAV-VEGF 165 samples as reported in Figure 1 (E).
AAV-VEGF 165 angiogenic effect within the tissue chamber
The transgene expression analysis confirmed the expression of human VEGF in the pectineus muscle within the chamber. Therefore, to assess the functional effect of rAAV transduction, a histological analysis was performed on the muscular flap in order to check for the angiogenic response induced by VEGF 165 overexpression. As previously reported by our group, VEGF 165 is able to induce the formation of small arterioles that can be visualized by an immunofluorescence staining for α-SMA. 16, 20, 23 Interestingly, the muscular tissue was preserved intact inside the collagen implant and the angiogenic effect of VEGF 165 could be confirmed by the presence of α-SMA-positive vessels surrounding the muscle fibres; AAV-LacZ-injected samples were used as controls (Figure 1(F) ).
Induction of new tissue formation
The detection of the rAAV DNA within the chamber and the angiogenic effect observed in the muscular flap suggested the feasibility of our combined tissue engineering-gene therapy approach. Thereby, in order to assess whether the expression of VEGF 165 by the transduced muscle fibres might improve the formation of new tissue within the chamber, we performed an Azan trichrome staining and quantified the newly formed tissue by means of ImageJ software. The samples were harvested at 1 month, time not sufficient for complete matrix collagen degradation; indeed, trabeculae were still detectable in all the samples, filling almost 20% of the section area. Due to the presence of the original collagen matrix, we were not able to quantify solely the newly formed tissue; instead we quantified the whole area occupied by the original matrix and the newly deposited tissue. Our quantification confirmed the data reported in the first described AVL model; indeed, in the samples with no muscle flap, the tissue filled 65% of the area, whereas in the AAV-LacZ group it raised up to 72% and in the AAV-VEGF 165 group it reached 80% of the section area (p < 0.05 AAV-LacZ vs control; p < 0.001 AAV-VEGF 165 vs control; p < 0.01 AAV-VEGF 165 vs AAV-LacZ). Representative images and quantification are reported in Figure 2 . Surprisingly, the muscle flap injected with AAVLacZ was also able to exert an effect on the chamber environment, leading to an increase in tissue formation but not at the same extent as observed upon transduction with AAV-VEGF 165 . A further histological analysis of the samples allowed us to obtain an accurate characterization of the newly formed tissue. The quantification of the number of cells present within the chamber, performed by quantifying the relative area occupied by DAPI nuclear staining, showed an increase in both the AAV-treated groups compared to the control one (7.84% ± 0.63% for control, 10.72% ± 0.52% for AAV-LacZ and 13.81% ± 0.55% for AAV-VEGF 165 ; p < 0.001 AAV-VEGF 165 vs control; p < 0.05 AAV-VEGF 165 vs AAV-LacZ). Representative images and quantification are reported in Supplementary  Figure 1 .
These results suggest that the presence of the muscle flap might contribute to new tissue formation by secreting growth factors. Moreover, muscle transduction by AAV-VEGF 165 is able to further enhance it.
Vessel formation is improved by VEGF 165 overexpression
The Azan trichrome staining also allowed us to detect a consistent number of new vessels interspersed within the collagen trabeculae of the artificial tissue (Figure 2(A) ). To assess whether new tissue formation might be associated or even favoured by an increased blood supply, as already showed in previous AVL models, 14 we analysed the presence of α-SMA-positive vessels by immunofluorescence staining, which showed that many new small arterioles were indeed contributing to the perfusion of the tissue chamber (Figure 3(A) ). A quantitative analysis revealed a pronounced increase in the number of vessels present within the chamber: 2.22 ± 0.24 vessels per section were detected in the control group, while 4.93 ± 0.42 and 8.27 ± 0.50 vessels per section were detected in AAV-LacZand AAV-VEGF 165 -treated animals, respectively (p < 0.05 AAV-LacZ vs control; p < 0.05 AAV-VEGF 165 vs control; p < 0.05 AAV-VEGF 165 vs AAV-LacZ) (Figure 3(B) ).
Although not observed in all samples at the same extent, the angiogenic effect in some sections was impressive, especially in close proximity to the vein graft. As reported in Figure 3(C) , the analysis of serial sections revealed that more than 10 vessels per section were detected only in the AAV-VEGF 165 group, whereas in the AAV-LacZ group vessels were always fewer. Interestingly, in some of the AAV-VEGF 165 sample sections, we observed the presence of few enlarged vessels, with a thin α-SMA cell layer and characterized by an irregular shape, resembling vascular lacunae, previously described by our group 16, 23 (Figure 4) .
To confirm that the α-SMA-positive structures were indeed vessels, a lectin staining was performed for the identification of endothelial cells. As shown in Supplementary Figure 2 , an inner layer of endothelial cells can be observed in close proximity to the α-SMA-positive structures and the vessel lumen can be recognized. Interestingly, the lectin staining highlighted the presence of endothelial cells not surrounded by α-SMA-positive cells, thus suggesting the presence of capillaries. Therefore, we performed a further histological analysis on the tissue sections for the identification of the different components of the newly formed tissue. Besides the presence of arterioles revealed by the α-SMA staining ( Figure 5(A) ), we were able to detect several lectin-positive vessels suggesting a strong angiogenic process ( Figure 5(B) ). The newly formed vascular network was interspersed within the newly deposited collagen matrix and several cell nuclei were detected, as reported in Figure 2 and 3. Thereby, we wondered whether fibroblasts were a cellular population composing the new tissue. Thus, a vimentin staining was performed and highlighted a massive presence of fibroblasts suggesting an important role in tissue formation ( Figure 5(C) ).
Discussion
In medicine, the research of alternative sources for tissue substitutes and innovative approaches to enhance tissue regeneration is a major challenge. Tissue engineering has largely spread out in this respect, and one of the key issues that is emerging nowadays is the demand for vascularization of the new templates in order to improve cell and tissue survival.
Several approaches aimed to enhance the formation of new vascularized tissue have been described so far, and recently, Morrison and colleagues showed that a microsurgical AVL-based method could lead to the formation of a highly vascularized tissue within a biological scaffold. Indeed, these authors reported that the insertion of an AVL into a fibrin-rich tissue chamber enhances the formation of a vascularized soft tissue that resembles a connective tissue. 13 More recently, a novel microsurgical model has been described, based on the usage of a commercially available cross-linked collagen/glycosaminoglycan (GAG) template as a new type of matrix to envelop an AVL in the rat groin. 14 Of interest, in this model the process of angiogenesis has been deeply characterized, and tensional and shear stress forces were shown to be the key factors for the angiogenic stimuli. 4 In order to improve this previous model and to foster vessel formation by the expression of angiogenic factors, such as VEGF, we took advantage of the gene transfer technology based on rAAV vectors. Indeed, a muscle pedicle, which is a suitable candidate for rAAV transduction, 24, 25 was inserted inside the collagen/GAG scaffold. For this purpose, in our new surgical model, we chose the pectineus muscle, which is close to both the loop and the chamber, in the rat groin. In addition, it was also selected due to its vascular and anatomical features. Thus, the muscular flap was inserted in the collagen/GAG implant, still connected to the circulation by a vascular pedicle that ensures tissue perfusion and long-term survival, features needed for transgene expression by the muscle fibres. At 1 month after surgery, we were able to recover collagen/GAG implants in which the muscle flap tissue was still intact and connected to the vasculature. Furthermore, the presence of rAAV genomes and the expression of the transgene could be detected; we also observed a strong angiogenic response in the muscle, as previously reported in other models. 16, 21, 23, 26 To better characterize our collagen chamber, we analysed the newly formed tissue and we observed a slight improvement in the tissue area in the presence of the muscle flap injected with a control vector, which was even increased upon VEGF 165 expression. Surprisingly, an increase in the new tissue area was also detected in the AAV-LacZ samples, and this effect might be due to the expression of proangiogenic factors, such as VEGF, in response to hypoxia by the muscular flap within the chamber. [27] [28] [29] Moreover, we observed that the extension of the area occupied by the new tissue correlated with the formation of α-SMA-positive vessels within the chamber. Indeed, newly formed vessels were detected in both LacZ and VEGF 165 expressing chambers, with a stronger effect in the VEGF 165 -treated animals, confirming the notion that, also in this model, VEGF exerts an angiogenic effect. A more detailed analysis on the vasculature showed that in the presence of VEGF the number of arterioles per section was increased, supporting and enhancing the finding that VEGF is an angiogenic factor, and in agreement with data previously reported in other mouse models. 16, 23 A characterization of the cellular populations composing the new tissue revealed the presence of endothelial cells suggesting an ongoing angiogenic process and the massive presence of fibroblasts which might be involved in matrix deposition.
Additionally, we reported the presence of some enlarged vessels, resembling the vascular lacunae observed previously in the VEGF-treated muscles, 16, 23 suggesting that the process of angiogenesis is mainly driven by VEGF in the described model.
Of notice, a strong angiogenic effect was observed not only in close proximity to the transduced muscle, likely sustained by the secreted factor, thus suggesting that the muscular flap might act as a bioreactor for secreted factors upon rAAV transduction.
Conclusion
The results obtained in this animal model confirmed the feasible use of AAV-VEGF 165 as a tool to enhance the formation of new tissue within an in vivo chamber for tissue engineering. Moreover, the increased number of α-SMA-positive vessels in the VEGF-treated animals suggested that the formation of new tissue might entail on the angiogenic process.
Our regeneration chamber looks as a promising tool in tissue engineering, particularly as it acts as an isolated chamber, which does not allow interference from the surrounding tissues. The creation of a highly vascularized tissue chamber which can be microsurgically transferred to another site, due to the presence of a vascular pedicle, might be appealing for reconstructive surgery.
As a future perspective, our chamber might be envisioned as a bioreactor and might be viewed as a tissue chamber for the in vivo expansion and differentiation of cells potentially enriched in precursor or stem cells.
